ID: ALA5282276

Max Phase: Preclinical

Molecular Formula: C67H111N21O20

Molecular Weight: 1530.75

Representations

Canonical SMILES:  CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(C)=O)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(N)=O

Standard InChI:  InChI=1S/C67H111N21O20/c1-12-34(8)52(64(107)79-39(54(69)97)20-16-26-74-66(70)71)87-63(106)51(33(6)7)85-55(98)35(9)77-65(108)53(36(10)89)88-62(105)49(31(2)3)84-46(92)30-76-56(99)40(21-17-27-75-67(72)73)80-59(102)43(28-38-18-14-13-15-19-38)83-58(101)42(23-25-47(93)94)81-57(100)41(22-24-45(68)91)82-61(104)50(32(4)5)86-60(103)44(29-48(95)96)78-37(11)90/h13-15,18-19,31-36,39-44,49-53,89H,12,16-17,20-30H2,1-11H3,(H2,68,91)(H2,69,97)(H,76,99)(H,77,108)(H,78,90)(H,79,107)(H,80,102)(H,81,100)(H,82,104)(H,83,101)(H,84,92)(H,85,98)(H,86,103)(H,87,106)(H,88,105)(H,93,94)(H,95,96)(H4,70,71,74)(H4,72,73,75)/t34-,35-,36+,39-,40-,41-,42-,43-,44-,49-,50-,51-,52-,53-/m0/s1

Standard InChI Key:  PCKPGLPAZRSTNN-DVWORILBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1530.75

Molecular Weight (Monoisotopic): 1529.8314

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Cuffaro D, Ciccone L, Rossello A, Nuti E, Santamaria S..  (2022)  Targeting Aggrecanases for Osteoarthritis Therapy: From Zinc Chelation to Exosite Inhibition.,  65  (20.0): [PMID:36250680] [10.1021/acs.jmedchem.2c01177]

Source

Source(1):

• Scientific Literature